659 POSTER Intraperitoneal application of the trifunctional antibody catumaxomab (anti-EpcAM x anti-CD3) for the treatment of peritoneal carcinomatosis due to GI cancer: Results of a phase I trial

首页> 外文期刊>European Journal of Cancer Supplements >659 POSTER Intraperitoneal application of the trifunctional antibody catumaxomab (anti-EpcAM x anti-CD3) for the treatment of peritoneal carcinomatosis due to GI cancer: Results of a phase I trial

【24h】

659 POSTER Intraperitoneal application of the trifunctional antibody catumaxomab (anti-EpcAM x anti-CD3) for the treatment of peritoneal carcinomatosis due to GI cancer: Results of a phase I trial

机译：659 POSTER腹膜内应用三功能抗体catumaxomab（抗EpcAM x抗CD3）治疗由GI癌引起的腹膜癌：I期试验的结果

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2005年第2期|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. First surgical experience of intraperitoneal treatment with the trifunctional antibody catumaxomab (anti-EpCam x anti-CD3) for epithelial ovarian cancer. [J] . Papanikolaou G, Fotopoulou C, Braicu I, Anticancer Research: International Journal of Cancer Research and Treatment . 2011,第8期

机译：三功能抗体catumaxomab（抗EpCam x抗CD3）腹膜内治疗上皮性卵巢癌的首次外科手术经验。
2. 5005 ORAL Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients [J] . S.Loibl, J.Pfisterer, P.Wimberger, European Journal of Cancer Supplements . 2007,第4期

机译：5005 ORAL腹膜内注入三功能双特异性抗体catumaxomab（抗EpCAM×抗CD3）的随机，多中心，2剂量水平，开放标签IIa期研究，以选择难治性铂类上皮性卵巢癌患者的更好剂量水平
3. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM × anti-CD3): a phase I study [J] . Martin Sebastian, Bernward Passlick, Hilke Friccius-Quecke, Cancer Immunology, Immunotherapy . 2007,第10期

机译：三功能单克隆抗体catumaxomab（抗EpCAM×抗CD3）治疗非小细胞肺癌患者：I期研究
4. Surgical Treatment of Advanced Gastric Cancer with Peritoneal Metastasis and the Clinical Trial of Intraperitoneal (I.P.) Administration with Hap-CBDCA in Peritoneal Carcinomatosis (P.C.) [C] . I. Mizuno, N. Mohri, A. Yasuda, International Gastric Cancer Congress . 2005

机译：具有腹膜转移的晚期胃癌的外科治疗及腹膜内（I.P.）腹膜癌症患者临床试验（第CB.）（P.C.）
5. Nutritional Risk in the Cancer Patient 65 and Older Undergoing Systemic Treatment via Phase I Clinical Trials [D] . Williams, Anna Cathy. 2019

机译：癌症患者65岁及以上经受I期临床试验的营养风险
6. Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer [O] . Maren Knödler, Justus Körfer, Volker Kunzmann, 2018

机译：研究Catumaxomab（抗EpCAM×抗CD3）治疗胃癌患者腹膜癌的II期随机试验
7. Immunotherapy of Peritoneal Carcinomatosis with the Antibody Catumaxomab in Colon, Gastric, or Pancreatic Cancer: An Open-Label, Multicenter, Phase I/II Trial [O] . Ströhlein Michael A., Lordick Florian, Rüttinger Dominik, 2011

机译：用结肠癌，胃癌或胰腺癌中的抗体Catumaxomab免疫治疗腹膜癌病：开放标签，多中心，I / II期试验

659 POSTER Intraperitoneal application of the trifunctional antibody catumaxomab (anti-EpcAM x anti-CD3) for the treatment of peritoneal carcinomatosis due to GI cancer: Results of a phase I trial

著录项

相似文献

相关主题

期刊订阅